Autoimmune Inc.

The Brigham and Women's Hospital, Inc.

The General Hospital Corporation

The United States of America As Represented by the Department of Health

Yeda Research and Develpment & Co. Ltd

Tel Aviv University

Hadasit Medical Research Services and Development Ltd.

Id Biomedical Corporation of Quebec

Howard L Weiner

David A Hafler

David Allen Hafler

Zhengyi Zhang

Francisco Javier Quintana

David E Trentham

Ahmad Al-Sabbagh

George S Eisenbarth

Charles B Carpenter

Zhengi Zhang

Galina Gabriely

Mohamed H Sayegh

George Eisenberth

Irun R Cohen

Yaron Ilan

David S Burt

Takatoku Oida

Ariel Miller

Mohamed Sayegh

Andre Pires Da Cunha

Dan Frenkel

Anna M Krichevsky

Ruth Maron

Peter Libby

Robert B Nussenblatt

Alan G Palestine

Merit Cudkowicz

Veronica Lifshitz

Eugene Ponomarev

Patricia A Nelson

Tatyana Veremeyko

Lior Mayo

James Berry

Oleg Butovsky

Reza Halse

Mauricio Farez

Merit E Cudkowicz

Francisco J Quintana

Described herein are compositions and methods relating to LAP-binding agents, including, for example, anti-LAP antibodies, and to their use in methods of treatment of cancer. LAP-binding agents affected both systemic and intra-tumor immunity and were shown effective to treat a broad spectrum of cancer types.

Treatment of cancer with anti-LAP monoclonal antibodies

Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.

Modulation of the immune response

Treatment of cancer with anti-lap monoclonal antibodies

Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA hsa-miR-155.

Micrornas in neurodegenerative disorders

The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, &#x3b2;-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with &#x3b2;-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.

Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

As described herein, lactosylceramide (LacCer) levels are up-regulated in the CNS during chronic experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). LacCer acts in an autocrine manner to trigger transcriptional programs that promote the recruitment and activation of CNS infiltrating monocytes and microglia, and neurodegeneration. In addition, increased B4GALT6 expression and LacCer levels were detected in CNS MS lesions in human patients. Finally, the inhibition of LacCer synthesis suppressed local CNS innate immunity and neurodegeneration in EAE, and interfered with the activation of human astrocytes in vitro. Thus, B4GALT6 is a therapeutic target for MS and other neuroinflammatory disorders.

Treating neurodegenerative disease

Methods for increasing the numbers of regulatory T cells (Treg), e.g., in a population of T cells or in a patient.

The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.

Methods of modulating immunity

Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.

Methods of treating cerebral amyloid angiopathy

The present invention relates to methods and kits for diagnosing multiple sclerosis (MS) in a subject. Particularly, the present invention relates to methods and kits for diagnosing a subtype of MS in a subject, the subtype selected from relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and a pathologic sub-type of MS lesions selected from Pattern I and Pattern II MS lesion.

Diagnosis of multiple sclerosis

Methods of treating, reducing the risk of developing, or delaying the onset of an inflammatory disease are disclosed. The methods involved providing a subject with or at risk of developing an inflammatory disease and administering to the subject an effective amount of a first therapeutic composition comprising miR-124. Further provided are methods of diagnosing a subject with or at risk of developing an inflammatory disease.

Treatment of inflammatory diseases using miR-124

Disclosed herein are methods for treating vascular disorders in mammals. The methods involve administering one or more agents selected from the group consisting of a heat shock protein (HSP), a therapeutically effective fragment and a therapeutically effective analog of a heat shock protein in a form suitable for mucosal administration. In some embodiments the heat shock protein of the method is mycobacterial HSP65. In some embodiments the heat shock protein is human HSP60. In some embodiments the heat shock protein is chlamydial HSP60. The method is of particular value in the treatment of atherosclerosis. Also disclosed are compositions useful for treating vascular disorders in mammals. The compositions include one or more agents selected from the group consisting of heat shock protein, therapeutically effective fragments and therapeutically effective analogs of said heat shock protein in aerosol or oral form. In some embodiments the heat shock protein of the composition is mycobacterial HSP65. In some embodiments the heat shock protein of the method is human HSP60. In some embodiments the heat shock protein is chlamydial HSP60. The composition is of particular value in the treatment of atherosclerosis.

Suppression of vascular disorders by mucosal administration of heat shock protein peptides

Growing community of inventors

Brookline, MA, United States of America

Howard L Weiner